Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Jamieson Wellness Inc T.JWEL

Alternate Symbol(s):  JWLLF

Jamieson Wellness Inc., together with its subsidiaries, develops, manufactures, distributes, markets, and sells the natural health products for human in Canada, the United States, China, and internationally. The company operates in two segments, Jamieson Brands and Strategic Partners. The Jamieson Brands segment manufactures, distributes, and markets branded natural health products, including vitamins, minerals, and supplements as well as sports nutrition products. The Strategic Partners segment provides contract manufacturing services to consumer health companies and retailers. It offers health and wellness supplements under the Jamieson brand; health, beauty, and wellness supplements under the Youtheory brand; and foundational formulas, including probiotics, multivitamins, fish oils, vitamin D, and solution-focused products for better sleep or digestion under the Progressive brand. The company also provides plant-based products under the Iron Vegan brand; natural health products f...


TSX:JWEL - Post by User

Post by retiredcfon Feb 27, 2026 1:03pm
20 Views
Post# 36914532

RBC

RBCTheir upside scenario target is $48.00. GLTA

February 27, 2026

Jamieson Wellness Inc.

Wellness Trends Still in Good Health
 

Our view: Solid Q4/25 results and 2026 guidance were largely in line with

our forecast notwithstanding modestly lower adjusted EBITDA margins due

to geographic mix. With 2026 revenue guidance implying ~$915MM at the

midpoint, we believe the company remains on a clear trajectory towards

achieving its $1B+ revenue target. Following estimate revisions, our $44

price target is unchanged.
 

Key points:

Capitalizing on structural health and wellness tailwinds. With strong

brand equity and category dominance in Canada (~40% household

penetration), Jamieson Wellness is well positioned to benefit from

structural tailwinds for VMS including aging populations in core markets,

increased adoption by younger demographics, higher disposable

incomes in emerging markets and a growing focus by consumers

on preventive healthcare. Against this backdrop, we believe current

valuation levels (11.8x FTM EV/EBITDA versus a long-term average of

~14.0x) represent an attractive accumulation opportunity given solid

execution, a healthy innovation pipeline, steady domestic consumption

and growing momentum in both the U.S. and China.
 

No surprises from 2026 guidance. 2026 guidance including revenue

growth of +9.0% to +13.7% YoY and adjusted EBITDA growth of +9.0% to

+13.4% (with margins flat YoY) was largely in line with our forecast and

consistent with the previously provided medium-term outlook. Drilling

down into 2026 guidance, management indicated that: (i) revenue

growth of +20%-30% YoY for China (on the back of +56% growth in 2025)

reflects ongoing momentum as performance marketing drives brand

awareness and conversion rate improvements (in 2025, trial conversion

rates increased +57% while repeat buyer conversion rates increased

+81%); (ii) revenue growth of +14%-19% for the U.S. (in USD) will be

driven by accelerating e-commerce growth and innovation (with a more

steady cadence to launches in 2026 versus 2025); (iii) revenue growth

of +4%-6% for Canada does not assume any pricing actions and reflects

healthy underlying consumption trends (category consumption was mid-

single digits for both dollars and units in Q4/25) supported by structural

tailwinds and innovation; and (iv) despite underlying margin expansion

in all segments of the business, consolidated adjusted EBITDA margins

are expected to be flat in 2026 reflecting geographic mix with accelerated

growth in China alongside a recovery in Strategic Partners (with both

having lower margin levels). Our 2026 forecast factors in revenue and

adjusted EBITDA growth of +11.2% and +11.6%, respectively.
 

Other notables from the quarter. (i) following a reduction in working

capital in Q4/25, management expects to be more active with share

repurchases in H2/26; (ii) building on the success in China to-date, the

company is beginning to assess incremental expansion opportunities in

Asia; and (iii) the company is actively looking at acquisition opportunities,

focusing on scaled quality brands in the U.S. with >$100MM in annual

revenues and digital expertise.



<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities